A newly developed oncolytic virus, SKV-012, has demonstrated promising results in preclinical studies and a phase I clinical trial for the treatment of advanced solid tumors.
Galapagos NV has divulged probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.
To overcome the current limitations of antitumor immunotherapy, in situ vaccine platforms based on intelligent microbes are gaining increased attention due to their ability to sustainably deliver drugs locally without causing severe systemic risks.
Tilt Biotherapeutics Ltd. has raised $25.6 million in a series B round that will fund phase II development of the lead oncolytic virus in the treatment of platinum-resistant ovarian cancer.
Both IL-15 and IL-2 are good options for cancer therapy, but IL-15 is considered superior due to lower vascular endothelial toxicity, stronger ability to expand natural killer and CD8+ T cells and weaker stimulation of T regulatory cells, but it has a short half-life and exerts severe adverse effects.
Neuboron Medtech Research Institute Ltd. has disclosed boron-containing lipoic acid derivatives and vesicle forms acting as boron neutron capture therapy (BNCT) agents reported to be useful for the treatment of cancer.
The U.K. National Institute for Health and Care Excellence (NICE) opened a late-stage assessment for drug-eluting stents (DES) with an eye toward costs, advising clinicians that they should implant the least expensive DES unit that is clinically appropriate for that patient while the assessment is underway.
Haisco Pharmaceutical Group Co. Ltd. has identified peptide-drug conjugates comprising a peptide targeting integrin αvβ3 (vitronectin) covalently bound to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
